{"id":84659,"date":"2023-02-22T05:15:19","date_gmt":"2023-02-22T05:15:19","guid":{"rendered":"http:\/\/kuwaitnewsgazette.com\/?guid=fee9f612af1b14f4e27694e113a41bb6"},"modified":"2023-02-22T05:15:19","modified_gmt":"2023-02-22T05:15:19","slug":"nyxoah-announces-inaugural-investor-analyst-meeting","status":"publish","type":"post","link":"https:\/\/kuwaitnewsgazette.com\/nyxoah-announces-inaugural-investor-analyst-meeting\/","title":{"rendered":"Nyxoah Announces Inaugural Investor & Analyst Meeting"},"content":{"rendered":"
\n

Nyxoah Announces Inaugural Investor & Analyst Meeting<\/strong><\/p>\n

Mont-Saint-Guibert, Belgium \u2013 February 21, 2023, 10:30pm CET \/ 4:30pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/strong>\u00a0(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will host its inaugural Investor & Analyst Meeting on March 23, 2022, from 4:00pm to 7:00pm ET.<\/p>\n

The event, which will be held at Nyxoah\u2019s New York City offices, will include a business update from the Company\u2019s senior management and presentations from key opinion leaders in the field of obstructive sleep apnea. The meeting will conclude with a Q&A session, followed by a reception.<\/p>\n

Investors interested in attending the meeting may do so by registering for the event at the following link:\u00a0Nyxoah Investor & Analyst Meeting 2023 (office.com)<\/u><\/a>. A live and archived webcast of the event will be available on the Company\u2019s investor relations website at\u00a0https:\/\/investors.nyxoah.com\/events<\/u><\/a>.<\/p>\n

About Nyxoah<\/strong>
\nNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).\u00a0Nyxoah\u2019s lead solution is the Genio\u00ae system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world\u2019s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.<\/p>\n

Following the successful completion of the BLAST OSA study, the Genio\u00ae system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors\u2019 therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.<\/p>\n

For more information, please visit\u00a0http:\/\/www.nyxoah.com\/<\/u><\/a>.<\/p>\n

Caution\u00a0<\/strong>\u2013 CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.<\/p>\n

Contacts:<\/strong>
\nNyxoah<\/strong>
\nDavid DeMartino, Chief Strategy Officer
\ndavid.demartino@nyxoah.com<\/a>
\n+1 310 310 1313<\/p>\n

Attachment<\/strong><\/p>\n